NEWS HIGHLIGHTSMedia Articles Related to Pulmicort Respules (Budesonide)
ACAAI: Combo Beats Budesonide Alone in Asthma (CME/CE)
Source: MedPage Today Allergy & Immunology [2009.11.12]
MIAMI BEACH (MedPage Today) -- Regardless of the asthma patient's age, treatment with a combination of budesonide and formoterol produced a greater improvement in lung function than budesonide pressurized metered-dose inhalers alone, researchers reported here.
Published Studies Related to Pulmicort Respules (Budesonide)
An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. [2009.09.19]
INTRODUCTION: In budesonide/formoterol (Symbicort(R) Turbuhaler(R), AstraZeneca, Lund, Sweden) maintenance and reliever therapy (SMART), patients with asthma take a daily maintenance dose of budesonide/formoterol, with the option of taking additional doses for symptom relief instead of a short-acting beta(2)-agonist (SABA). This study assesses the cost-effectiveness of SMART compared with usual care in patients with mild-to-moderate persistent asthma treated by general practitioners in the Netherlands from a societal perspective... CONCLUSIONS: Treating primary care patients with mild-to-moderate persistent asthma with SMART instead of ICS plus bronchodilators does not affect health outcomes and does not increase costs; therefore, is likely to be an alternative for guideline-directed treatment, from a health and economic perspective.
Aerosolized L epinephrine vs Budesonide for Postextubation Stridor A Randomized Controlled Trial. [2009.09.03]
Objective: To compare the efficacy and adverse effects of aerosolized Lepinephrine vs budesonide in the treatment of postextubation stridor... However, epinephrine showed a more sustained effect.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. [2009.09.01]
CONCLUSIONS: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade >or=2 diarrhea associated with ipilimumab therapy.
Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. [2009.07]
Grapefruit juice (GFJ) inhibits CYP3A activity in the gut wall, thereby decreasing first-pass metabolism of CYP3A substrates...
Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing. [2009.07]
BACKGROUND: The goal of asthma therapy is to control symptoms using minimal pharmacologic intervention. OBJECTIVE: To evaluate the efficacy and tolerability of once-daily budesonide/formoterol vs once-daily budesonide in patients stable with twice-daily budesonide/formoterol... CONCLUSIONS: Pulmonary function and asthma control were more effectively maintained with all budesonide/formoterol regimens vs once-daily budesonide and with twice-daily budesonide/formoterol at twice the daily formoterol dose vs both once-daily budesonide/formoterol doses.
Clinical Trials Related to Pulmicort Respules (Budesonide)
Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when
given to asthma patients aged 12 years and above.
Assess the Efficacy and Safety of Rhinocort Aqua [Completed]
The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5
years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and
stuffy noses.
New Version Pulmicort Turbuhaler USA Children [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently
approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents
who have asthma. In addition the study evaluated the functionality of the new inhaler at the
end of its intended life.
New Version Pulmicort Turbuhaler USA Adults [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently
approved Pulmicort Turbuhaler with a new version of the inhaler, in adult patients who have
asthma and are currently being treated with inhaled steroids. In addition the study evaluated
the functionality of the new inhaler at the end of its intended life.
Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children [Completed]
A one year study comparing the safety and effectiveness of Pulmicort (0. 5mg strength given
once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the
evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children
aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will
receive 5mg strength SINGULAR.
|
